Among 18 analysts covering The Bank Of New York Mellon Corporation (NYSE:BK), 8 have Buy rating, 0 Sell and 10 Hold. Therefore 44% are positive. The Bank Of New York Mellon Corporation had 43 analyst reports since July 22, 2015 according to SRatingsIntel. The rating was downgraded by JP Morgan on Friday, January 6 to “Neutral”. The stock of Bank of New York Mellon Corp (NYSE:BK) earned “Overweight” rating by JP Morgan on Thursday, January 7. The firm earned “Buy” rating on Wednesday, September 9 by Deutsche Bank. The rating was downgraded by Keefe Bruyette & Woods on Friday, January 20 to “Mkt Perform”. The stock has “Buy” rating by Deutsche Bank on Tuesday, January 26. The stock has “Overweight” rating by Barclays Capital on Friday, January 22. Barclays Capital maintained Bank of New York Mellon Corp (NYSE:BK) on Tuesday, January 3 with “Overweight” rating. The firm earned “Hold” rating on Wednesday, April 12 by Jefferies. The firm has “Buy” rating given on Friday, January 22 by UBS. Deutsche Bank maintained Bank of New York Mellon Corp (NYSE:BK) on Thursday, June 16 with “Buy” rating. See Bank of New York Mellon Corp (NYSE:BK) latest ratings:
24/04/2017 Broker: Credit Suisse Old Rating: Hold New Rating: Neutral Downgrade
12/04/2017 Broker: Jefferies Rating: Hold New Target: $52.00 Maintain
07/04/2017 Broker: Deutsche Bank Rating: Buy Old Target: $55.00 New Target: $54.00 Target Down
05/04/2017 Broker: RBC Capital Markets Rating: Hold New Target: $52.00 Maintain
20/01/2017 Broker: Keefe Bruyette & Woods Old Rating: Outperform New Rating: Mkt Perform Downgrade
06/01/2017 Broker: JP Morgan Old Rating: Overweight New Rating: Neutral Downgrade
03/01/2017 Broker: Barclays Capital Rating: Overweight Old Target: $48 New Target: $55 Maintain
28/12/2016 Broker: Raymond James Old Rating: Outperform New Rating: Strong Buy New Target: $5.00 Upgrade
21/11/2016 Broker: Buckingham Research Old Rating: Buy New Rating: Neutral Downgrade
The stock of Flex Pharma Inc (NASDAQ:FLKS) is a huge mover today! About 85,170 shares traded or 48.86% up from the average. Flex Pharma Inc (NASDAQ:FLKS) has declined 72.61% since September 19, 2016 and is downtrending. It has underperformed by 84.28% the S&P500.The move comes after 8 months positive chart setup for the $66.35M company. It was reported on Apr, 26 by Barchart.com. We have $4.01 PT which if reached, will make NASDAQ:FLKS worth $5.97M more.
Among 2 analysts covering Flex Pharma (NASDAQ:FLKS), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Flex Pharma had 3 analyst reports since August 21, 2015 according to SRatingsIntel. The rating was downgraded by Zacks to “Hold” on Friday, August 21. The stock of Flex Pharma Inc (NASDAQ:FLKS) earned “Hold” rating by Zacks on Wednesday, September 2. As per Friday, October 14, the company rating was downgraded by Cantor Fitzgerald.
Flex Pharma, Inc. is a biotechnology company. The company has market cap of $66.35 million. The Firm develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps . It currently has negative earnings. The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
Analysts await Flex Pharma Inc (NASDAQ:FLKS) to report earnings on May, 3. They expect $-0.63 earnings per share, down 3.28% or $0.02 from last year’s $-0.61 per share. After $-0.48 actual earnings per share reported by Flex Pharma Inc for the previous quarter, Wall Street now forecasts 31.25% negative EPS growth.
Investors sentiment increased to 0.97 in Q4 2016. Its up 0.07, from 0.9 in 2016Q3. It increased, as 45 investors sold Bank of New York Mellon Corp shares while 317 reduced holdings. 122 funds opened positions while 230 raised stakes. 846.88 million shares or 1.27% more from 836.26 million shares in 2016Q3 were reported. Moreover, Commonwealth Of Pennsylvania School Empls Retrmt has 0.05% invested in Bank of New York Mellon Corp (NYSE:BK). Rockshelter Capital Limited Liability Com holds 3.49% or 236,103 shares. Moreover, Pax World Management Ltd Co has 0.97% invested in Bank of New York Mellon Corp (NYSE:BK). Fdx Incorporated invested 0.07% of its portfolio in Bank of New York Mellon Corp (NYSE:BK). The Florida-based Sabal Trust Co has invested 0.06% in Bank of New York Mellon Corp (NYSE:BK). Timber Hill Limited Co, a Connecticut-based fund reported 70,673 shares. 10 stated it has 0.6% of its portfolio in Bank of New York Mellon Corp (NYSE:BK). State Board Of Administration Of Florida Retirement System reported 0.22% of its portfolio in Bank of New York Mellon Corp (NYSE:BK). Ftb Advisors Inc has invested 0.04% in Bank of New York Mellon Corp (NYSE:BK). 6,970 are owned by Arrow Financial. Covington invested in 0.18% or 43,665 shares. Pekin Singer Strauss Asset Mngmt Il holds 88,504 shares. Cove Street Ltd Liability stated it has 0.48% of its portfolio in Bank of New York Mellon Corp (NYSE:BK). Ameriprise Finance holds 14.64M shares or 0.38% of its portfolio. Wealthtrust Axiom has 5,875 shares for 0.1% of their portfolio.
The Bank of New York Mellon Corporation is an investments company. The company has market cap of $48.75 billion. The Firm operates businesses through two divisions: Investment Management and Investment Services. It has a 14.61 P/E ratio. The Firm also has an Other segment, which includes the leasing portfolio, corporate treasury activities , derivatives and other trading, corporate and bank-owned life insurance and renewable energy investments, and business exits.
